Search

Ranjana Tavorath

from Basking Ridge, NJ
Get Report
Connected to:
Alison T Tavoularis, 64Marilyn C Tavoularis, 69Robert J Tavoularis, 40Stephen D Tavoulareas, 57Scott P Tavres, 46Susan Tavrides, 54Mona A Tavss, 47Hazel C Taw, 76Ruhina S Tawa, 49Vikrant P Tawade, 54

Ranjana Tavorath Phones & Addresses

  • Basking Ridge, NJ
  • New York, NY
  • Needham, MA
  • 31 Bush Rd, Denville, NJ 07834 (973) 263-0361 (973) 263-3762
  • Cordova, TN
  • Short Hills, NJ
  • Princeton, NJ
  • Cranbury, NJ
  • 40 Ramapo Dr, Basking Ridge, NJ 07920

Work

Company: Novartis oncology 2012 Position: Executive director clin research physician

Education

School / High School: Lady Hardinge Medical College / University of Delhi

Skills

Oncology • Clinical Development • Clinical Trials • Medical Affairs • Cro • Medicine • Clinical Research • Pharmaceutical Industry • Drug Development • Gcp • Biotechnology • Drug Discovery • Life Sciences • Therapeutic Areas • Ctms

Languages

English

Awards

Healthgrades Honor Roll

Ranks

Certificate: Internal Medicine, 1992

Industries

Pharmaceuticals

Specialities

Oncology • Medical Oncology

Professional Records

Medicine Doctors

Ranjana Tavorath Photo 1

Dr. Ranjana Tavorath, East Hanover NJ - MD (Doctor of Medicine)

View page
Specialties:
Oncology
Medical Oncology
Address:
1 Health Plz, East Hanover, NJ 07936
(862) 778-4118 (Phone)
Certifications:
Internal Medicine, 1992
Medical Oncology, 1995
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
Lady Hardinge Medical College / University of Delhi
Medical School
U Tenn
Medical School
Kingston Hosp
Medical School
Royal Free Hosp
Medical School
Meml Sloan-Kettering Canc Ctr
Ranjana Tavorath Photo 2

Ranjana Tavorath

View page
Specialties:
Internal Medicine
Hematology
Medical Oncology

Resumes

Resumes

Ranjana Tavorath Photo 3

Consultant

View page
Location:
Cranbury, NJ
Industry:
Pharmaceuticals
Work:
Novartis Oncology since 2012
Executive Director Clin Research Physician
Novartis Aug 2007 - Mar 2012
Senior Medical Director PI3Kinase Program
Bristol-Myers Squibb Dec 2008 - Mar 2010
Group Director Oncology Medical Strategy
Novartis Feb 2006 - Jul 2007
Director -Clin Development and Med Affairs US
Novartis Nov 2004 - Jan 2006
Assoc Director/Clin Research Physician Oncology
Education:
Memorial Sloan Kettering Cancer Ctr 1992 - 1995
Fellowship, Hem/Onc Fellowship
Skills:
Oncology
Clinical Development
Clinical Trials
Medical Affairs
Cro
Medicine
Clinical Research
Pharmaceutical Industry
Drug Development
Gcp
Biotechnology
Drug Discovery
Life Sciences
Therapeutic Areas
Ctms

Publications

Us Patents

Use Of Somatostatin Analogs In Meningioma

View page
US Patent:
20120302500, Nov 29, 2012
Filed:
Aug 9, 2012
Appl. No.:
13/570607
Inventors:
Gabriela Gruia - Hoboken NJ, US
Ranjana Tavorath - Short Hills NJ, US
Assignee:
NOVARTIS AG - Basel
International Classification:
A61K 38/12
A61P 35/00
US Classification:
514 111
Abstract:
The present invention relates to the use of a Somatostatin (SRIF) analog which has a high binding affinity to human SSTR1,2,3,5, or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical composition for the treatment of meningioma.

Use Of Somatostatin Analogs In Meningioma

View page
US Patent:
20130303450, Nov 14, 2013
Filed:
Apr 22, 2013
Appl. No.:
13/867210
Inventors:
Gabriela Gruia - Hoboken NJ, US
Ranjana Tavorath - Short Hills NJ, US
Assignee:
NOVARTIS AG - Basel
International Classification:
A61K 38/12
US Classification:
514 97
Abstract:
The present invention relates to the use of a Somatostatin (SRIF) analog which has a high binding affinity to human SSTR1,2,3,5, or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical composition for the treatment of meningioma.

Use Of Somatostatin Analogs In Meningioma

View page
US Patent:
20100273719, Oct 28, 2010
Filed:
Nov 25, 2008
Appl. No.:
12/743274
Inventors:
Gabriela Gruia - Hoboken NJ, US
Ranjana Tavorath - Short Hills NJ, US
Assignee:
NOVARTIS AG - Basel
International Classification:
A61K 38/12
A61P 35/00
B65D 85/00
US Classification:
514 192, 2065241, 2064595
Abstract:
The present invention relates to the use of a Somatostatin (SRIF) analog which has a high binding affinity to human SSTR1,2,3,5, or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical composition for the treatment of meningioma.

Dosage Regimen For An Alpha-Isoform Selective Phosphatidylinositol 3-Kinase Inhibitor

View page
US Patent:
20200069670, Mar 5, 2020
Filed:
Aug 29, 2019
Appl. No.:
16/556111
Inventors:
- Basel, CH
Marie-Caroline Germa - Croissy-sur-Seine, FR
Cristian Massacesi - Neuilly Sur-Seine, FR
Christine Fritsch - Steinbach, FR
Christian René Schnell - Hegenheim, FR
Ranjana Tavorath - Basking Ridge NJ, US
International Classification:
A61K 31/4439
A61K 9/00
Abstract:
The present invention relates to methods of treating or preventing a proliferative disease in a patient in need thereof by orally administering a therapeutically effective amount of an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor compound of formula (I) or a pharmaceutically acceptable salt thereof for at least two five-consecutive day cycle, wherein said compound is not administered to the patient for a period of about two days to about three days between said five-consecutive day cycles; the use of said compound of formula (I) or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating or preventing a proliferative disease administered in accordance with said dosage regimen; therapeutic regimen comprising administration of said compound of formula (I) or a pharmaceutically acceptable salt thereof in accordance with said dosage regimen; and related pharmaceutical compositions and packages thereof.

Dosage Regimen For An Alpha-Isoform Selective Phosphatidylinositol 3-Kinase Inhibitor

View page
US Patent:
20180078540, Mar 22, 2018
Filed:
Sep 29, 2017
Appl. No.:
15/719636
Inventors:
- Basel, CH
Marie-Caroline Germa - Croissy-sur-Seine, FR
Cristian Massacesi - Neuilly Sur-Seine, FR
Christine Fritsch - Steinbach, FR
Christian René Schnell - Hegenhein, FR
Ranjana Tavorath - Basking Ridge NJ, US
International Classification:
A61K 31/4439
A61K 9/00
Abstract:
The present invention relates to methods of treating or preventing a proliferative disease in a patient in need thereof by orally administering a therapeutically effective amount of an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor compound of formula (I) or a pharmaceutically acceptable salt thereof for at least two five-consecutive day cycle, wherein said compound is not administered to the patient for a period of about two days to about three days between said five-consecutive day cycles; the use of said compound of formula (I) or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating or preventing a proliferative disease administered in accordance with said dosage regimen; therapeutic regimen comprising administration of said compound of formula (I) or a pharmaceutically acceptable salt thereof in accordance with said dosage regimen; and related pharmaceutical compositions and packages thereof.

Dosage Regimen For An Alpha-Isoform Selective Phosphatidylinositol 3-Kinase Inhibitor

View page
US Patent:
20170000778, Jan 5, 2017
Filed:
Dec 3, 2014
Appl. No.:
15/101155
Inventors:
Emmanuelle di Tomaso - Lexington MA, US
Marie-Caroline Germa - Croissy-sur-Seine, FR
Cristian Massacesi - Neuilly Sur-Seine, FR
Christine Fritsch - Steinbach, FR
Christian Rene Schnell - Hegenhein, FR
Ranjana Tavorath - Basking Ridge NJ, US
International Classification:
A61K 31/4439
A61K 9/00
Abstract:
The present invention relates to methods of treating or preventing a proliferative disease in a patient in need thereof by orally administering a therapeutically effective amount of an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor compound of formula (I) or a pharmaceutically acceptable salt thereof for at least two five-consecutive day cycle, wherein said compound is not administered to the patient for a period of about two days to about three days between said five-consecutive day cycles; the use of said compound of formula (I) or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating or preventing a proliferative disease administered in accordance with said dosage regimen; therapeutic regimen comprising administration of said compound of formula (I) or a pharmaceutically acceptable salt thereof in accordance with said dosage regimen; and related pharmaceutical compositions and packages thereof.
Control profile
Ranjana Tavorath from Basking Ridge, NJ Get Report